Apple

AI in life sciences faces challenges like data bias, cybersecurity threats, and performance failures, despite its potential in drug discovery and personalized medicine.

Huawei unveiled Mate 70 series, featuring HarmonyOS NEXT, a satellite paging system, and improved processor, aiming to break from U.S. tech. Prices start at 5,499 yuan, competing with Apple's iPhone 16. Huawei plans to expand HarmonyOS ecosystem to 100,000 apps. Mate 70 series uses SMIC-made Kirin 9100 chipset, boosting Huawei's market recovery in China.

Hearst Networks UK launches 'Unbreakable,' a short-form series on Crime+Investigation, featuring survivors of abuse sharing their stories. Hosted by Nina Aouilk, each episode provides a platform for personal testimonies of resilience and recovery from various forms of violence and exploitation.

Citi Research reports Apple planning iOS 18.2 release in Dec., introducing smart features impacting iPhone replacement cycle. Citi maintains buy rating with $255 target, forecasting iPhone sales of 227M in 2024, 246M in 2025, and 253M in 2026. iOS 18.1 launched in Oct. with limited generative AI in U.S. English, expected in EU by Apr. 2024. Apple to upgrade Siri in 2025, fully available in 2026. Holiday survey shows 48% favor iPhones, slight dip in interest for high-end models.

The FDA has authorized nearly 1,000 AI or machine learning-enabled medical devices by August 2024, with a significant increase in approvals since 2015. AI is enhancing diagnostics, treatment planning, and patient care, especially in radiology and cardiology. Companies like GE Healthcare and Siemens Healthineers lead in AI medical devices, focusing on imaging and diagnostics. Regulatory pathways are evolving to accommodate AI's rapid growth in healthcare.

Goldman Sachs predicts AI-driven revenue growth companies will take off in 2025, transitioning from AI infrastructure investments. 11 companies are realizing revenue gains from AI technology, with Phase 3 AI stocks expected to outperform. Valuations for Phase 3 stocks are more reasonable, offering potential for multiple expansion.

ChatGPT, OpenAI's AI chatbot, has seen rapid growth and expanded partnerships, including with Apple for Apple Intelligence. OpenAI faces challenges such as internal departures, copyright lawsuits, and ethical concerns, including a voice mimicking Scarlett Johansson. GPT-4o, OpenAI's latest model, offers voice capabilities but faces controversies. OpenAI continues to innovate with features like Advanced Voice Mode and SearchGPT, while addressing regulatory and ethical issues.

Life Time launches 100 new on-demand classes and more meditations via its app, expanding its digital library with 50 new videos and weekly releases.

Omron Healthcare received FDA de novo authorization in Oct 2024 for home blood pressure monitors with AI-powered AFib detection. The monitors use IntelliSense AFib algorithm for medical-grade accuracy, aiming to address the AFib epidemic. Omron plans to launch the monitors in early 2025, focusing on proactive health management with AI technologies.

Fanaroff: Research grants from American Heart Association and National Institutes of Health; consulting fees from Abbott Laboratories. Vora: Consulting fees from Medtronic. Mehran: Institutional research grants from AstraZeneca, Bayer, Beth Israel Deaconess, Bristol Myers Squibb/Sanofi, CSL Behring, Eli Lilly/Daiichi Sankyo, Medtronic, Novartis, OrbusNeich; consulting fees from Boston Scientific, Abbott Vascular, Medscape, Siemens Medical Solutions, Roivant Sciences Inc, Sanofi; consulting (no fees) for Regeneron Pharmaceuticals Inc; institutional consulting fees from Abbott Vascular, Spectranetics/Phillips/Volcano Corporation, Bristol Myers Squibb, Novartis, Watermark Research; Executive committee member for Janssen Pharmaceuticals and Bristol Myers Squibb; <1% equity in Claret Medical and Elixir Medical. Granger: Research grants from Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Pfizer, Armetheon, AstraZeneca, US Food and Drug Administration, GlaxoSmithKline, The Medicines Company, Medtronic Foundation, Medtronic Inc, Novartis; consulting fees from Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Pfizer, Abbvie, Armetheon, AstraZeneca, Eli Lilly, Gilead, GlaxoSmithKline, Hoffmann-La Roche, The Medicines Company, National Institutes of Health, Novartis, Sirtex, Verseon, Apple, Medscape, LLC, Merck, Novo Nordisk, Roche Diagnostics, Rho Pharmaceuticals. Goodman: Research grant support and/or speaker/consulting honoraria from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Daiichi-Sankyo, Eli Lilly, Esperion, Fenix Group International, Ferring Pharmaceuticals, GlaxoSmithKline, HLS Therapeutics, Janssen/Johnson & Johnson, Luitpold Pharmaceuticals, Matrizyme, Merck, Novartis, Novo Nordisk A/C, Pfizer, Regeneron, Sanofi, Servier, Tenax Therapeutics, Heart and Stroke Foundation of Ontario/University of Toronto, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Duke Clinical Research Institute, PERFUSE. Aronson: Employee of Bristol Myers Squibb. Windecker: Institutional research and educational grants from Abbott, Amgen, Bayer, BMS, CSL Behring, Boston Scientific, Biotronik, Edwards Lifesciences, Medtronic, Polares, Sinomed. Alexander: Research grants from Bristol Myers Squibb, Boehringer Ingelheim, AstraZeneca, CryoLife, CSL Behring, US Food and Drug Administration, National Institutes of Health, Sanofi, VoluMetrix; consulting fees from Pfizer, Bristol Myers Squibb, AbbVie Pharmaceuticals, CSL Behring, Novo Nordisk, Portola Pharmaceuticals, Quantum Genomics, Teikoku Pharmaceuticals, VA Cooperative Studies, Zafgen. Lopes: Research grants from Bristol Myers Squibb, Pfizer, Amgen, Inc, GlaxoSmithKline, Medtronic PLC, Sanofi Aventis; consulting fees from Bristol Myers Squibb, Pfizer, Boehringer Ingelheim, Bayer AG. The other authors report no conflicts.